Exelixis stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 69 to 76.
As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.
IBD's proprietary RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks compares to the rest of the market.
Decades of market research shows that the stocks that go on to make the biggest gains often have an 80 or better RS Rating as they begin their largest price moves. See if Exelixis stock can continue to rebound and clear that threshold.
Looking For Winning Stocks? Try This Simple Routine
Is Exelixis Stock A Buy?
Exelixis stock has been trading below its 200-day moving average and out of a proper buying point. While it's not currently an ideal time to buy shares, see if the stock goes on to offer and clear a proper buy point. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech firm posted 0% EPS growth last quarter, while sales growth came in at -6%.
Exelixis stock holds the No. 66 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm and Vertex Pharmaceuticals are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
